1. Home
  2. AIMD vs ALLR Comparison

AIMD vs ALLR Comparison

Compare AIMD & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIMD

Ainos Inc.

HOLD

Current Price

$2.43

Market Cap

16.9M

Sector

Health Care

ML Signal

HOLD

Logo Allarity Therapeutics Inc.

ALLR

Allarity Therapeutics Inc.

HOLD

Current Price

$1.13

Market Cap

20.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIMD
ALLR
Founded
1984
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.9M
20.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AIMD
ALLR
Price
$2.43
$1.13
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$9.25
AVG Volume (30 Days)
43.8K
176.2K
Earning Date
11-13-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$113,037.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
178.19
N/A
52 Week Low
$1.78
$0.61
52 Week High
$5.00
$2.35

Technical Indicators

Market Signals
Indicator
AIMD
ALLR
Relative Strength Index (RSI) 45.20 45.64
Support Level $2.03 $1.06
Resistance Level $2.56 $1.35
Average True Range (ATR) 0.18 0.10
MACD 0.08 0.01
Stochastic Oscillator 78.21 46.82

Price Performance

Historical Comparison
AIMD
ALLR

About AIMD Ainos Inc.

Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.

About ALLR Allarity Therapeutics Inc.

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.

Share on Social Networks: